LANOXIN (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of
Digitalis lanata. The term "digitalis" is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence "glycosides").
Heart Failure: LANOXIN is indicated for the treatment of mild to moderate heart failure. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified.
Atrial Fibrillation: LANOXIN is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation.
Media Articles Related to Lanoxin (Digoxin)
Congestive Heart Failure (CHF)
Source: MedicineNet Amyloidosis Specialty [2014.12.29]
Title: Congestive Heart Failure (CHF)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 12/29/2014 12:00:00 AM
Congestive Heart Failure
Source: MedicineNet Impotence (ED) Specialty [2013.10.08]
Title: Congestive Heart Failure
Category: Diseases and Conditions
Created: 10/16/2013 7:54:00 PM
Last Editorial Review: 10/8/2013 12:00:00 AM
Patients rarely learn of at-home provider quality data
Source: Caregivers / Homecare News From Medical News Today [2015.01.14]
Say your aunt Betty is ready to be discharged from the hospital after a close call with congestive heart failure.
Published Studies Related to Lanoxin (Digoxin)
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the
pharmacokinetics of digoxin. 
To investigate the impact of the direct Factor Xa inhibitor darexaban
administered in a modified-release formulation (darexaban-MR) on the
pharmacokinetic (PK) profile of digoxin. In this Phase I, randomized,
double-blind, two-period crossover study (8 days for each treatment, 10 days
washout), 24 healthy subjects received darexaban-MR 120 mg once/day (qd) +
digoxin 0.25 mg qd in one treatment period, and placebo + digoxin 0.25 mg qd in
the other treatment period...
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. 
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with
Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. [2011.03]
The aim of this study was to investigate whether multiple doses of the oral and highly selective dipeptidyl peptidase-4 inhibitor linagliptin affect the steady-state pharmacokinetics of the P-glycoprotein substrate digoxin. This single-center, open-label, two-period cross-over study involved healthy subjects (n = 20), randomized to treatment sequence AB or BA, where A comprised 0.25 mg digoxin qd for 5 days, then 0.25 mg digoxin qd plus 5 mg linagliptin qd for 6 days, and B comprised 0.25 mg digoxin qd for 11 days...
Digoxin for preventing or treating neonatal respiratory distress syndrome. [2011.01.19]
CONCLUSIONS: Although hemodynamic disturbances play a role in the overall pathogenesis of respiratory distress syndrome, the specific contribution of early congestive heart failure (unrelated to hemodynamically significant patent ductus arteriosus) does not appear to be a significant factor in RDS. Treatment with digoxin has no proven value in infants solely affected with RDS.
Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). [2010.09]
Several retrospective studies have raised concerns regarding digoxin therapy in select subgroups of heart failure patients... No benefit with digoxin use was observed in this study, underscoring the need to reassess the role of digoxin in the contemporary management of heart failure.
Clinical Trials Related to Lanoxin (Digoxin)
A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults [Recruiting]
The primary objective of this study is to determine the effect of repeat oral doses of
eliglustat 150 mg twice daily (BID) (or 100 mg BID for CYP2D6 poor metabolizers) on the
pharmacokinetics (PK) of orally administered digoxin 0. 25 mg in healthy adult subjects. This
will be a single-site, open-label study in 2 staggered cohorts of healthy adult subjects.
The study will comprise a screening period (between Day - 45 and Day -2), treatment period 1
(Day - 1 to Day 4), treatment period 2 (Day 11 to Day 18), and a safety follow-up visit (Day
24 ± 1). There will be a 10-day washout between dosing of study drug in Period 1 and Period
2. The duration of each subject's participation in the study, inclusive of the screening and
follow-up visits, will be approximately 10 weeks.
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients [Recruiting]
The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics
(PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.
A Trial of Digoxin Before Second-Trimester Abortion [Recruiting]
Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin [Recruiting]
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Subjects [Recruiting]
The purpose of this study is to study how the body processes digoxin and the effect of
dulaglutide on how digoxin is processed by the body. Information about any side effects that
may occur will also be collected.
This study is for research purposes only and is not intended to treat any medical condition.
This research study requires that a blood sample be obtained and stored for future research
involving genetic analysis.
Reports of Suspected Lanoxin (Digoxin) Side Effects
Toxicity TO Various Agents (16),
Cardiac Failure Congestive (5),
Atrial Fibrillation (5),
Asthenia (5), more >>